Analysts have reiterated their target price for DarioHealth at $22.25 per share. They are maintaining their outlook based on updated assumptions regarding discount rates and profit margins.
What's in the News
- DarioHealth announced the addition of six new employer clients and deployed a new value-based pricing model, aligning payments with member engagement and clinical outcomes (Client Announcements).
- The Board of Directors has launched a comprehensive strategic review, considering a range of options including a potential sale, merger, or continued standalone operations. The company has engaged Perella Weinberg Partners as financial advisor (Considering Multiple Strategic Alternatives).
- DarioHealth raised $17.5 million in private placements through the issuance of common shares and pre-funded warrants (Private Placements).
- Five new contracts with self-insured employers went live, featuring DarioHealth's cardiometabolic suite focused on prediabetes, diabetes, and hypertension care (Client Announcements).
- The company completed a 1-for-20 stock split in August 2025 (Stock Splits & Significant Stock Dividends).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $22.25 per share.
- Discount Rate has fallen slightly from 8.95% to 8.77%.
- Revenue Growth projections are stable, holding at approximately 18.28%.
- Net Profit Margin expectations remain nearly the same, with a minimal decrease from 8.46% to 8.46%.
- Future P/E ratio has declined modestly from 15.14x to 15.06x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.